drugset
Drugs / Dendritic Cell Immunization
last change May 2026 re-read 9 days ago

Dendritic Cell Immunization

Vaccine

Developed for
glioblastoma · melanoma
Investigated by
Adelson Medical Research · Key Biologics, LLC · M.D. Anderson Cancer Center · National Cancer Institute (NCI) · Oslo University Hospital · Prometheus Laboratories

Trials 2

today NCT03548571 · Ph 2/3 NCT00338377 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 missed
Phase 2 NCT00338377 Feb 2006 → Feb 2030 expected melanoma M.D. Anderson Cancer Center Active not recruiting Missed primary
Phase 2/31 trial
Phase 2/3 NCT03548571 Apr 2018 → Dec 2025 glioblastoma Oslo University Hospital Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Dendritic cell immunization ClinicalTrials.gov intervention name — accepted as the source's own label NCT03548571 ↗
1

NCT00338377 ↗
Modality Vaccine “the vaccine of dendritic cells” NCT00338377 ↗
Route Intravenous “given by vein over 20-30 minutes” NCT00338377 ↗